Skip to content

Precision Preoperative Embolization of Pelvic Tumors to Improve Surgical Outcomes

Precision Preoperative Embolization of Pelvic Tumors to Improve Surgical Outcomes

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05633134
Enrollment
120
Registered
2022-12-01
Start date
2023-02-01
Completion date
2024-10-31
Last updated
2022-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Embolization, Pelvic Tumor

Brief summary

The main purpose of this study is to assess the efficacy of precision preoperative embolization in decreasing operative blood loss, reducing surgical complications in pelvic tumor surgery. Furthermore the study aims at describing the vascularity in a series of pelvic tumors, and to correlate this with perioperative blood loss.

Detailed description

The main purpose of this study is to assess the efficacy of precision preoperative embolization in decreasing operative blood loss, reducing surgical complications in pelvic tumor surgery,which including poor wound healing,nerve injury,and pelvic organs dysfunction. Furthermore the study aims at describing the vascularity in a series of pelvic tumors,which contains four grade:poor,moderate,rich and abundant and to correlate this with perioperative blood loss.

Interventions

PROCEDUREArteriography and precision preoperative embolization

Arteriography and transcatheter arterial embolization of pelvic tumors 0-24 hours prior to surgery.

PROCEDUREArteriography

Arteriography of pelvic tumors 0-24 hours prior to surgery.

Sponsors

Peking University People's Hospital
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Primary or metastatic pelvic tumor * Confirmed by contrast-enhanced magnetic resonance imaging (MRI) or computed tomography (CT) of the pelvic * Planned surgical resection

Exclusion criteria

* Contrast medium allergy * Uncontrolled or concurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

Design outcomes

Primary

MeasureTime frameDescription
Perioperative blood lossMeasured intraoperativelyPerioperative blood loss measured intraoperatively

Secondary

MeasureTime frameDescription
Adverse events related to angiography or embolizationWithin 2 postoperative daysIncluding symptoms of nerve compression, pelvic organ ischemia injury
Adverse events related to surgeryWithin 30 postoperative daysincluding poor wound healing,nerve injury,pelvic organ dysfunction
Vascularization grade of pelvic tumorsAt the angiographic procedure prior to embolization performed 0-24 hours before surgeryit contains four grades:poor、moderate、rich、abundant
postoperative blood lossWithin 2 postoperative daysblood loss measured through the drainage within 2 postoperative days

Contacts

Primary ContactXIN ZHI
zhixindd@163.com861088326220
Backup ContactPING YIN
13810080018@163.com861088326220

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026